Stocktoria
Intellia Therapeutics, Inc. NTLA
Intellia Therapeutics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $67.7M | $57.9M | $36.3M | $52.1M | $33.1M | $58.0M | $43.1M | $30.4M | $26.1M | $16.5M |
| R&D expense | $388.9M | $466.3M | $435.1M | $420.0M | $229.8M | $150.4M | $108.4M | $89.1M | $67.6M | $31.8M |
| Operating income | -$441.0M | -$534.3M | -$515.3M | -$458.2M | -$267.9M | -$136.6M | -$106.4M | -$90.9M | -$69.6M | -$32.2M |
| Income tax | $0 | — | — | — | — | — | — | — | — | $0 |
| Net income | -$412.7M | -$519.0M | -$481.2M | -$474.2M | -$267.9M | -$134.2M | -$474.2M | -$85.3M | -$67.5M | -$31.6M |
| EPS (diluted) | $-3.81 | $-5.25 | $-5.42 | $-6.16 | $-3.78 | $-2.40 | — | — | — | — |
| Operating cash flow | -$394.7M | -$348.9M | -$394.1M | -$333.3M | -$225.0M | -$49.9M | -$103.2M | -$61.3M | -$65.3M | $36.1M |
| Free cash flow | -$395.9M | -$354.7M | -$408.1M | -$346.8M | -$237.8M | -$53.5M | -$110.0M | -$67.6M | -$75.4M | $29.9M |
| Cash & equivalents | $155.5M | $189.2M | $226.7M | $523.5M | $123.4M | $160.0M | $57.2M | $58.9M | $340.7M | $273.1M |
| Total assets | $842.1M | $1.2B | $1.3B | $1.5B | $1.3B | $676.3M | $334.3M | $347.3M | $376.2M | $299.0M |
| Total liabilities | $170.7M | $319.1M | $250.8M | $284.5M | — | — | — | — | — | — |
| Shareholders' equity | $671.4M | $872.0M | $1.1B | $1.2B | $1.0B | $527.1M | $269.9M | $277.9M | $300.6M | $209.8M |
Growth · year-over-year · Revenue CAGR 17%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +16.9% | +59.6% | -30.4% | +57.7% | -43.0% | +34.5% | +41.6% | +16.5% | +58.5% | — |
| Free cash flow growth | — | — | — | — | — | — | — | — | -351.7% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.